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and metabolic functions, and circulating inflammatory
markers might help to better characterise these
patients.
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The diagnosis of COPD relies on the demonstration of
fixed airflow limitation in the absence of less frequent
diseases causing airways obstruction. Guidelines have
for decades used the ratio of FEV1/VC or FEV1/FVC as
the measurements of choice; this has rarely been the
cause of debate whereas the cut-off values for the ratio
have been intensely debated. The fixed ratio of 0.7
causes under-diagnosis of COPD in younger adults and
over-diagnosis in the elderly whereas the use of lower
limit of normal presumes that less than 5% of elderly
asymptomatic smokers can have COPD as ‘normality’ is
defined according to statistics only.
More importantly, however, the current diagnostic
guidance does not take into account that we define
COPD as 1) a disease characterised by an abnormal
inflammatory response, 2) a disease with a frequently
occurring extrapulmonary component – and 3) that we
know that one of the main subtypes of COPD,
emphysema, often does not lead to airflow limitation in
its earliest stages. We will need to decide whether we
want to keep our simple diagnostic criteria and sub-
sequently try to describe the individual patient’s
features by “sub-grouping” COPD or whether our
diagnostic criteria should mirror how we define the
disease.
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The most recent definition of COPD clearly states that
the disease is both preventable and treatable. The
knowledge on interventions that may improve the
clinical course of COPD is constantly expanding and the
COPD patients of today are facing a totally different
approach from the health professionals compared to the
situation 20 years ago. This means that the clinical
course of the disease need no longer result in a con-
tinuing decline of lung function, repeated exacerbations
and development of respiratory failure. Whereas
smoking cessation in the early stage of COPD and long
term oxygen treatment in the end-stage disease were in
the past thought to be the only two modalities affecting
the long term clinical course of the disease, it is now
documented that also pharmacological treatment with
long acting antimuscarinic agents, long acting beta-2-
agonists and inhaled corticosteroids, rehabilitation
comprising physical exercise and immunisation against
influenza affects the long term prognosis and improves
the health related quality of life of the patients. Also
the treatment of acute exacerbations with non-invasive
ventilation has revolutionised the clinical practice by
reducing both mortality and the need for intubation.
In order to implement these options with success, the
timing of intervention is essential. In this context the
more widespread use of spirometry, assessment of the
severity of dyspnea and identification of patients with
repeated exacerbation is mandatory. The pulmonary
community has a major obligation in assuring that the
knowledge from the successful controlled trials will be
implemented in the clinical practice.
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The usefulness of exhaled nitric oxide (eNO) measure-
ment is still controversial in chronic obstructive pul-
monary disease (COPD). However, modelling measure-
ments of eNO from multiple flows may provide measures
of parenchymal and airway inflammation and could
potentially be used to monitor inflammation in COPD. In
my PhD study I will investigate any possible correlation
between local inflammation and systemic inflammation
in COPD patients and relate it to presence/development
of cardiac disease.
Ninety one (91) COPD patients recruited in the
ECLIPSE study with FEV1 ranging from 17-77% have been
seen every three months in the first year and every six
months in the following eighteen month period. I aim to
use two compartment nonlinear modelling of multiple
flow rates eNO at 10, 30, 50, 100 and 200 mL·s–1, but
currently only raw eNOs are available and eNO50 is used
to indicate airway inflammation. The following
biochemical markers of inflammation in serum are used:
IL-6, IL-8, TNFα, Clara cell secretory protein-16 (CC-16),
and Surfactant Protein D (SPD).
Neither eNO50 nor any of the systemic markers varied
according to age, gender or GOLD stage except IL6 which
increased by age. There was no correlation between
eNO50 and any of the systemic markers. There was an
association between TNFα and PARC (r=.26, p=.01) but no
other inter-relations between systemic markers. IL-6 was
significantly elevated in subjects with ischemic heart
disease (7.27 vs 2.13 pg/mL, p<.001) as was CC-16 (6.17
vs. 4.86 ng/mL, p=.03), none of the others markers were
related to heart disease at baseline.
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Future analyses of my study cohort can hopefully
provide more data on the association between local and
systemic inflammation and cardiac comorbidities in
COPD.
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Background: Numerous studies have demonstrated
evidence of oxidative stress in COPD, in both respiratory
tract lining fluids and biopsies. Antioxidant response in
airway inflammatory cells to a pro-oxidative
environment is however poorly understood. We have
previously demonstrated an enhanced antioxidant
enzyme activity in macrophages from asthmatics. This
study was performed to assess whether a similar adap-
tation in intra-cellular antioxidants occurred in subjects
with COPD. The activities of enzymatic antioxidants
were examined in alveolar mixed cell populations and
compared to healthy age-matched controls (ACs) and
young adults, to permit the relative contributions of
disease state and natural ageing to be disentangled.
Methods: Airway leukocytes were obtained by bronchos-
copy-based lavage and cellular activities of Cu,Zn
superoxide dismutase (SOD1), glutathione peroxidase
(GPx), catalase (CAT) and glutathione reductase (GSSG-
red) were determined. In addition, cellular glutathione
and glutathione disulphide concentrations were
quantified to determine cellular redox status.
Results: No differences in the activity of the major
enzymatic antioxidants or intra-cellular GSH concen-
tration were observed between COPD patients and ACs.
In contrast, significantly reduced SOD1 (p<0.001), GPx
(p=0.04) and GSSG-red (p=0.01) activities were
observed in the ACs relative to the young adult group. In
contrast, catalase activity was elevated in the ACs
(p=0.001), but again with no further enhancement in
the COPD group.
Conclusion: These data demonstrate a loss of adaptive
plasticity associated with ageing, rather than a COPD-
specific down regulation of antioxidant defences. These
data do however highlight that in COPD, unlike asthma,
the imposition of oxidative stress does not induce
protective adaptations, implying a greater sensitivity to
oxidant injury in vivo.
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Nerve growth factor (NGF) and neurotrophin-3 (NT-3)
belong to the neurotrophin family and are important
growth- and survival factors for neurons. Lately, they
have also been shown to be potent inflammatory
mediators as well as factors promoting tissue repair
processes. Increased levels of neurotrophins have
previously been shown in the airways of patients with
asthma and sarcoidosis.
In this study we investigated the levels of neuro-
trophins in the airways of patients with moderate to
severe COPD (n=25), healthy non-smokers (n=12) and
asymptomatic smokers (n=16). We found decreased
levels of NGF and NT-3 in bronchoalveolar lavage fluid
(BALF) in COPD patients and asymptomatic smokers as
compared to healthy non-smokers. These findings
suggest that smoking per se decreases the release of
neurotrophins in the airways. Structural cells, such as
epithelial cells and fibroblasts, are known sources of
neurotrophins. We found that NGF secretion was
decreased from cultured human lung fibroblasts
exposed to cigarette smoke extract.
These results indicate that smoking have inhibitory
effects on neurotrophin secretion in the airways. The
functional consequence of lower levels of neurotrophins
in the airways of smokers and COPD patients is still
unknown and further studies are required to elucidate
the role of neurotrophins in inflammatory pulmonary
diseases.
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Chronic airway inflammation is a key feature in the
pathogenesis of COPD, and inhaled corticosteroids (ICS)
are widely used to alleviate airway inflammation in
COPD. We tested if non-invasive markers of airway
inflammation are related to lung function in COPD, or if
these markers can predict responsiveness to ICS.
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